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Background
Familial adenomatous polyposis (FAP) is a colon cancer
syndrome with a prevalence of 1:10:000, hallmarked by
100s to 1000s of precancerous colonic polyps and nearly
100% lifetime risk of developing colon cancer at an aver-
age age of 39 years in the absence of colon surveillance
and surgery. Mutations in the APC gene lead to FAP or
an attenuated form called AFAP with reduced polyp
numbers and cancer risk. Mutation detection fails using
DNA based technology in 20% of FAP and 50% of
AFAP patients due to testing limitations, inability to
determine significance of DNA change, or other respon-
sible genes. A subset of disease causing APC mutations
may be due to non-coding or even coding variants that
result in RNA splice defects.
Methods
A RNA-based assay has been developed to screen APC
mRNA for splice defects in mutation-negative FAP and
AFAP patients. Primers and PCR conditions were devel-
oped for five overlapping amplicons that cover exons
1-14 and the beginning of exon 15 in the APC mRNA.
PCR products from the cDNA of patients were run on
agarose gels and examined for atypical products.
Results
To date, cDNA from 14 mutation-negative families has
been tested, and two mutations resulting in splice
defects have been identified when other standard techni-
ques failed to demonstrate loss-of-function mutations.
One is a single nucleotide change, deep in intron 4 that
generates a splice acceptor site, an additional exon
(exon 4A), that includes a new stop codon. The second
is a 1.5-kb deletion in intron 14 which causes deletion
of exon 14 in the mRNA transcript; exon 13 is spliced
to exon 15, resulting in an out-of-frame stop codon.
Both families present as AFAP.
Conclusions
This is a useful assay to compliment DNA-based testing
in APC mutation-negative patients or patients with a
variant of uncertain significance. Additionally, to address
cases where undetected mutations affect the stability of
the resultant transcript, allelic imbalance can be exam-
ined in amplicons containing one of the common APC
single nucleotide polymorphisms (SNPs) using real-time
PCR.
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